This finding suggests that pharmacological modulation of the CXCL9/CXCR3 axis could be a therapeutic strategy to boost T cell recruitment, thereby making also the immune-desert tumors [2] amenable to cancer immunotherapy. This evidence concerns the gene CXCL9 and cancer.